Skip to main content
SpringerLink
Log in

In vitro evaluation of combination of EGCG and Erlotinib with classical chemotherapeutics on JAR cells

  • Published:
In Vitro Cellular & Developmental Biology - Animal Aims and scope Submit manuscript

Abstract

Gestational Trophoblastic Neoplasia (GTN) is a term used for a group of malignant gynecological tumors including choriocarcinoma. Low-risk neoplasias can be cured using single agents Methotrexate (MTX) and actinomycin-D (ACD), but in certain cases, decreased responsiveness and serious side effects occur. Therefore, researchers have been attempting to find new treatment modalities. One of the most popular way for increasing cancer patient survival rates is supporting treatment with adjuvant molecules or chemosensitizers. For this purpose, we investigated epigallocatechin-3-gallate (EGCG), a green tea cathecin, and Erlotinib, an EGFR tyrosine kinase inhibitor, as single agents and combined with MTX or ACD. In accordance with this, JAR (human placenta choriocarcinoma) cell line was used as an in vitro model and MTT, LDH, caspase-3 activation, RT-PCR, and Western Blot analyses were performed to investigate the effects of the test materials. Our studies demonstrate that combination of Erlotinib and EGCG with MTX and ACD decreases JAR cell proliferation and metastatic HER2 protein synthesis and increases caspase-3 activation compared to ACD or MTX alone. In addition, significant increase was observed in the apoptotic Bax gene, but no notable protein synthesis occurred in the Western Blot analysis, which suggests that combination of Erlotinib and EGCG with classical chemotherapeutics ACD or MTX may lead the JAR cells to apoptosis, but not by a mitochondrial pathway. All the results indicate that the synergetic effect of Erlotinib and EGCG with classical chemotherapeutics may help to increase patient survival rates of choriocarcinoma, but the detailed mechanism needs further investigation.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4

Similar content being viewed by others

References

  • Bachawal SV, Wali VB, Sylvester PW (2010) Enhanced antiproliferative and apoptotic response to combined treatment of γ-tocotrienol with erlotinib or gefitinib in mammary tumor cells. BMC Cancer 10:84

    Article  PubMed  PubMed Central  Google Scholar 

  • Bagley RG, Ren Y, Kurtzberg L, Weber W, Bangari D, Brondyk W, Teicher BA (2012) Human choriocarcinomas: placental growth factor-dependent preclinical tumor models. Int J Oncol 40:479–486

    PubMed  Google Scholar 

  • Cavazzoni A, Alfieri RR, Cretella D, Saccani F, Ampollini L, Galetti M, Galvani E (2012) Combined use of anti-ErbB monoclonal antibodies and erlotinib enhances antibody-dependent cellular cytotoxicity of wild-type erlotinib-sensitive NSCLC cell lines. Mol Cancer 11:1

    Article  Google Scholar 

  • Chen YX, Lv WG, Chen HZ, Ye F, Xie X (2009) Methotrexate induces apoptosis of human choriocarcinoma cell line JAR via a mitochondrial pathway. European Journal of Obstetrics & Gynecology and Reproductive Biology 143:107–111

    Article  CAS  Google Scholar 

  • Creagh EM, Conroy H, Martin SJ (2003) Caspase-activation pathways in apoptosis and immunity. Immunol Rev 193:10–21

    Article  CAS  PubMed  Google Scholar 

  • Dimas K, Sakellaridis N (2015) Choriocarcinoma. Reference Module in Biomedical Sciences. Elsevier, Oxford, pp 1–3

    Google Scholar 

  • Filla MS, Kaul KL (1997) Relative expression of epidermal growth factor receptor in placental cytotrophoblasts and choriocarcinoma cell lines. Placenta 18:17–27

    Article  CAS  PubMed  Google Scholar 

  • Fotakis G, Timbrell JA (2006) In vitro cytotoxicity assays: comparison of LDH, neutral red, MTT and protein assay in hepatoma cell lines following exposure to cadmium chloride. Toxicol Lett 160:171–177

    Article  CAS  PubMed  Google Scholar 

  • Fülöp V, Vegh G, Doszpod J (2001) The c-erbB-related oncoproteins in normal placenta and in gestational trophoblastic diseases (in vitro study). Orv Hetil 142:1147–1154

    PubMed  Google Scholar 

  • Han SN, Amant F, Leunen K, Devi UK, Neven P, Berteloot P, Vergote I (2012) Treatment of high-risk gestational trophoblastic neoplasia with weekly high-dose methotrexate–etoposide. Gynecol Oncol 127:47–50

    Article  CAS  PubMed  Google Scholar 

  • Hu F, Wei F, Wang Y, Wu B, Fang Y, Xiong B (2015) EGCG synergizes the therapeutic effect of cisplatin and oxaliplatin through autophagic pathway in human colorectal cancer cells. J Pharmacol Sci 128:27–34

    Article  CAS  PubMed  Google Scholar 

  • John M, Rajalekshmy T, Nair B, Augustine J, Schultz G, Nair K, Balaram P (1997) Expression of epidermal growth factor and its receptor in gestational trophoblastic diseases. Oncol Rep 4:177–182

    CAS  PubMed  Google Scholar 

  • Kim PJ, Lim HC, Kim DW, Lee YS (2004) In vitro interaction of Taxol with other antitumor drugs in the established choriocarcinoma cell lines. Korean Journal of Obstetrics and Gynecology 47:76–82

    Google Scholar 

  • Kim MJ, Yun HS, Hong EH, Lee SJ, Baek JH, Lee CW, Hwang SG (2013) Depletion of end-binding protein 1 (EB1) promotes apoptosis of human non-small-cell lung cancer cells via reactive oxygen species and Bax-mediated mitochondrial dysfunction. Cancer Lett 339:15–24

    Article  CAS  PubMed  Google Scholar 

  • Ko JC, Chiu HC, Syu JJ, Jian YJ, Chen CY, Jian YT, Lin YW (2014) Tamoxifen enhances erlotinib-induced cytotoxicity through down-regulating AKT-mediated thymidine phosphorylase expression in human non-small-cell lung cancer cells. Biochem Pharmacol 88:119–127

    Article  CAS  PubMed  Google Scholar 

  • Kong ANT, Yu R, Chen C, Mandlekar S, Primiano T (2000) Signal transduction events elicited by natural products: role of MAPK and caspase pathways in homeostatic response and induction of apoptosis. Arch Pharm Res 23:1–16

    Article  CAS  PubMed  Google Scholar 

  • Kuang YH, Shen T, Chen X, Sodani K, Hopper-Borge E, Tiwari AK, Chen ZS (2010) Lapatinib and erlotinib are potent reversal agents for MRP7 (ABCC10)-mediated multidrug resistance. Biochem Pharmacol 79:154–161

    Article  CAS  PubMed  Google Scholar 

  • Lecumberri E, Dupertuis YM, Miralbell R, Pichard C (2013) Green tea polyphenol epigallocatechin-3-gallate (EGCG) as adjuvant in cancer therapy. Clin Nutr 32:894–903

    Article  CAS  PubMed  Google Scholar 

  • Lee J, Kim YJ, Ryu JC (2010) Study on teratogenic effects of methotrexate; alteration of gene expression pattern in human placenta choriocarcinoma (JEG-3) cells. BioChip Journal 4:189–196

    Article  CAS  Google Scholar 

  • Lok CA, Ansink AC, Grootfaam D, Velden J, Verheijen RH, Marianne J (2006) Treatment and prognosis of post term choriocarcinoma in the Netherlands. Gynecol Oncol 103:698–702

    Article  PubMed  Google Scholar 

  • Mahmood T, Yang PC (2012) Western blot: technique, theory, and trouble shooting. N Am J Med Sci 4:429

    Article  PubMed  PubMed Central  Google Scholar 

  • Mazur AJ, Nowak D, Mannherz HG, Malicka-Błaszkiewicz M (2009) Methotrexate induces apoptosis in CaSki and NRK cells and influences the organization of their actin cytoskeleton. Eur J Pharmacol 613:24–33

    Article  CAS  PubMed  Google Scholar 

  • Moroni M, Veronese S, Schiavo R, Carminati O, Sorensen BS, Gambacorta M, Siena S (2001) Epidermal growth factor receptor expression and activation in nonseminomatous germ cell tumors. Clin Cancer Res 7:2770–2775

    CAS  PubMed  Google Scholar 

  • Rosell R, Carcereny E, Gervais R, Vergnenegre A, Massuti B, Felip E, Palmero R, Garcia Gomez R, Pallares C, Sanchez JM, Porta R, Cobo M, Garrido P, Longo F, Moran T, Insa A, De Marinis F, Corre PR (2012) Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial. The lancet oncology 13:239–246

    Article  CAS  PubMed  Google Scholar 

  • Roskoski R (2014) The ErbB/HER family of protein-tyrosine kinases and cancer. Pharmacol Res 79:34–74

    Article  CAS  PubMed  Google Scholar 

  • Savikko J, Rintala JM, Rintala S, Koskinen P (2015) Epidermal growth factor receptor inhibition by erlotinib prevents vascular smooth muscle cell and monocyte–macrophage function in vitro. Transpl Immunol 32:175–178

    Article  CAS  PubMed  Google Scholar 

  • Shen Y, Yang J, Zhao J, Xiao C, Xu C, Xiang Y (2015) The switch from ER stress-induced apoptosis to autophagy via ROS-mediated JNK/p62 signals: a survival mechanism in methotrexate-resistant choriocarcinoma cells. Exp Cell Res 334:207–218

    Article  CAS  PubMed  Google Scholar 

  • Shim D, Kang HY, Jeon BW, Kang SS, Chang SI, Kim HY (2004) Protein kinase B inhibits apoptosis induced by actinomycin D in ECV304 cells through phosphorylation of caspase 8. Arch Biochem Biophys 425:214–220

    Article  CAS  PubMed  Google Scholar 

  • Singh BN, Shankar S, Srivastava RK (2011) Green tea catechin, epigallocatechin-3-gallate (EGCG): mechanisms, perspectives and clinical applications. Biochem Pharmacol 82:1807–1821

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Sobhakumari A, Schickling BM, Love-Homan L, Raeburn A, Fletcher EV, Case AJ, Simons AL (2013) NOX4 mediates cytoprotective autophagy induced by the EGFR inhibitor erlotinib in head and neck cancer cells. Toxicol Appl Pharmacol 272:736–745

    Article  CAS  PubMed  Google Scholar 

  • Tse KY, Ngan HY (2012) Gestational trophoblastic disease. Best Practice & Research Clinical Obstetrics & Gynaecology 26:357–370

    Article  CAS  Google Scholar 

  • Tuncer ZS, Vegh GL, Fulop V, Genest DR, Mok SC, Berkowitz RS (2000) Expression of epidermal growth factor receptor-related family products in gestational trophoblastic diseases and normal placenta and its relationship with development of postmolar tumor. Gynecol Oncol 77:389–393

    Article  CAS  PubMed  Google Scholar 

  • Turan T, Karacay O, Tulunay G, Boran N, Koc S, Bozok S, Kose MF (2006) Results with EMA/CO (etoposide, methotrexate, actinomycin D, cyclophosphamide, vincristine) chemotherapy in gestational trophoblastic neoplasia. Int J Gynecol Cancer 16:1432–1438

    Article  CAS  PubMed  Google Scholar 

  • Xiang Y, Li Z, Cui Q, Yang X, Song H (2000) Expression of epidermal growth factor receptor in gestational trophoblastic tumours. Zhongguo yi xue ke xue yuan xue bao. Acta Academiae Medicinae Sinicae 22:555–557

    CAS  PubMed  Google Scholar 

  • Zhou X, Agazie YM (2012) The signaling and transformation potency of the overexpressed HER2 protein is dependent on the normally-expressed EGFR. Cell Signal 24(1):140–150

    Article  CAS  PubMed  Google Scholar 

  • Zhu Y, Wang S, Lin F, Li Q, Xu A (2014) The therapeutic effects of EGCG on vitiligo. Fitoterapia 99:243–251

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgements

This research was supported financially by the Commission of Scientific Research Projects of Anadolu University, Turkey (Project no: 1305F104) “Gestasyonel koryokarsinoma tedavisinde yeni tedavi modalitelerinin araştırılması”.

Author information

Authors and Affiliations

  1. Gynecology and Obstetrics Department, Eskişehir Osmangazi University Medical Faculty, Eskişehir, Turkey

    Elçin Telli & S. Sinan Özalp

  2. Biology Department, Anadolu Üniversitesi Faculty of Science, Eskişehir, Turkey

    Hatice Genç, Burcugül Altuğ Tasa & A. Tansu Koparal

Authors
  1. Elçin Telli
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Hatice Genç
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Burcugül Altuğ Tasa
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. S. Sinan Özalp
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. A. Tansu Koparal
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Hatice Genç.

Ethics declarations

Conflict of interest

The authors have declared that there is no conflict of interest.

Additional information

Editor: Tetsuji Okamoto

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Telli, E., Genç, H., Tasa, B.A. et al. In vitro evaluation of combination of EGCG and Erlotinib with classical chemotherapeutics on JAR cells. In Vitro Cell.Dev.Biol.-Animal 53, 651–658 (2017). https://doi.org/10.1007/s11626-017-0145-2

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11626-017-0145-2

Keywords

Search

Navigation